The French pharmaceutical company Sanofi will acquire the American Principia Biopharma for 3.68 billion dollars (3.11 billion euros). Americans are developing treatments for autoimmune diseases.
The acquisition has the unanimous approval of the boards of directors of Sanofi and Principia, announced the French company in a press release.
Sanofi has worked with Principia for three years on BTK’168, an inhibitor in the treatment of multiple sclerosis and other central nervous system disorders.
Sanofi expects to close the deal this year.